Sun Pharma incorporates subsidiary company in China
Mumbai: Sun Pharmaceutical Industries Limited has announced the incorporation of a subsidiary company, Sun Pharma (Hainan) Company Limited, in China.
The new entity was established on July 16, 2025.
In a regulatory filing with BSE, Sun Pharma stated that the newly formed company will do localization of products. These products will be manufactured at prospective partners in China for sales locally.
Sun Pharma will own (directly or through any of its subsidiaries) 100 percent equity in the new Company.
In addition to its international expansion, the company has also launched LEQSELVI (deuruxolitinib) 8 mg tablets, indicated for the treatment of adults with severe alopecia areata, in the U.S. LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks.
Read also: Sun Pharma unveils Leqselvi in US for severe Alopecia Areata
On the clinical research front, Sun Pharma has received a key regulatory green light in India.
Earlier this month, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) recommended granting permission to initiate a Phase III clinical trial for the new drug Gefapixant Tablets 45 mg, based on the bioequivalence (BE) study submitted by Sun Pharma Laboratories. This recommendation was made following a detailed review of the BE study report presented during the SEC Pulmonary meeting held on 28th May 2025.
Read also: Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant
Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.
